Work

Remdesivir for Patients Hospitalized With COVID-19: Evidence of Effectiveness From Cohort Studies in the Omicron Era

Year: 2024

Type: article

Abstract: Remdesivir is the only antiviral approved for treatment of persons hospitalized for coronavirus disease 2019 (COVID-19). This supplement presents new information from real-world cohort studies that report reduced mortality in at-risk populations and reduction in readmission for COVID-19 in the Omicron era.

Source: Clinical Infectious Diseases

DOI: 10.1093/cid/ciae515

Author: Daniel R Kuritzkes

Institutions: Brigham and Women's Hospital, Harvard University

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,001